Patients in Rural Communities Struggle to Access Newer Tumor-Targeting Radiotracers

Why It Matters

The findings highlight a trade‑off between diagnostic accuracy and geographic accessibility, prompting health systems to rethink tracer deployment to ensure rural patients receive timely cancer imaging. Addressing these disparities could reduce treatment delays and improve outcomes for underserved populations.

Key Takeaways

• Gallium‑68 PET tracers rose from 33% (2017) to >90% (2020).
• Rural patients traveled ~130 miles farther for gallium exams versus indium‑111.
• Copper‑64 DOTATATE use grew to 40.6% by 2023, easing travel burdens.
• Copper tracer adoption narrowed urban‑rural access gap for PET imaging.
• Policy recommendation: keep gallium in high‑volume centers, deploy copper in small markets.

Pulse Analysis

The transition from indium‑111 SPECT imaging to gallium‑68 PET tracers marked a major advance for neuroendocrine tumor detection, offering higher resolution and faster results. However, the ultra‑short half‑life of gallium‑68 means it must be produced on‑site, limiting distribution to facilities with cyclotrons or generator capabilities. This technical constraint has unintentionally widened the care gap between metropolitan hospitals and rural clinics, where patients often lack nearby PET/CT scanners and must endure long journeys for imaging.

A retrospective Medicare claims study encompassing roughly 250,000 scans quantified the disparity. By 2020, gallium‑68 accounted for over 90% of neuroendocrine imaging, yet rural patients faced an average additional 130‑mile commute compared with the older indium‑111 agent. The emergence of copper‑64 DOTATATE, whose 12‑hour half‑life permits regional distribution, reversed much of this trend. Its utilization climbed from 21% in 2021 to 40.6% in 2023, delivering comparable diagnostic value while dramatically shortening travel distances. The data suggest that when copper‑64 is the sole option, the urban‑rural gap virtually disappears, underscoring the importance of tracer selection in access planning.

For policymakers and health system leaders, the study offers a clear roadmap: concentrate gallium‑68 production in high‑volume, urban centers where economies of scale offset manufacturing costs, and expand copper‑64 availability in peripheral markets. Such a hybrid strategy could preserve the clinical advantages of PET imaging while mitigating geographic inequities. Future research should explore reimbursement models, tele‑radiology collaborations, and mobile PET units to further bridge the divide, ensuring that advances in molecular imaging translate into universal patient benefit.